Sign inJoin waitlistJoin the waitlist

Lauren Weintraub

Associate Program Director · Albany Medical College

Credentials: · · · ·

History

Albany Medical College
Present

Children's Hospital At Montefiore
2011–2012
Pediatrics
Mount Sinai Hospital
2008–2011
Tufts Univ Sch of Med
2004–2008

Research

Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations
Journal of Allergy and Clinical Immunology · 2020 · 118 citations
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma
Journal of Clinical Oncology · 2025 · 90 citations
Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors
Pediatric Blood & Cancer · 2020 · Last of 4 authors · 35 citations

Adam Levy
3 papers
David Korones
3 papers
Jeffrey Andolina
3 papers
RP
Roshal Patel
3 papers · 2 as a resident
Acacia Bowden
2 papers · 1 as a resident
Birte Wistinghausen
2 papers
Chana Glasser
2 papers · 2 as a resident
GR
Gavrielle Rood
2 papers · 1 as a resident
George Turco
2 papers · 2 as a fellow
JT
Juli Tomaino
2 papers
Kevin Bielamowicz
2 papers
Matthew Barth
2 papers

Clinical trials

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2033
Quality of End-of-Life Care for Children With Cancer
Site PI · Recruiting
Children's Oncology Group
2026–2031
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028